Intriguingly, we found that emodin plus anti-PD-L1 therapy (2.5 mg/kg every 3 days) resulted in a smaller tumor size and tumor volume than anti-PD-L1 monotherapy (5 mg/kg every 3 days), suggesting that the combination use of emodin and anti-PD-L1 therapy has great potential to enhance anti-tumor efficacy and reduce the degree of dose related anti-PD-L1 toxicity (Fig. 7H–J). The gene discussed is CD274; the disease is neoplasm.